Trials / Completed
CompletedNCT03235232
BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension
Randomized Clinical Trial to Compare the Efficacy and Safety of BREMEN Eye Drops Versus Combigan in Subjects With Open Angle Glaucoma or Ocular Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 406 (actual)
- Sponsor
- EMS · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the clinical efficacy of the BREMEN eye drops in the treatment of primary open-angle glaucoma or intraocular hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BREMEN eye drops | 1 drop in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks. |
| DRUG | Combigan® | 1 drop of Combigan® in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks. |
Timeline
- Start date
- 2021-02-01
- Primary completion
- 2023-07-31
- Completion
- 2023-10-31
- First posted
- 2017-08-01
- Last updated
- 2024-02-20
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT03235232. Inclusion in this directory is not an endorsement.